These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
370 related articles for article (PubMed ID: 24065240)
1. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Lillicrap D Blood; 2013 Nov; 122(23):3735-40. PubMed ID: 24065240 [TBL] [Abstract][Full Text] [Related]
2. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Lillicrap D Hematology Am Soc Hematol Educ Program; 2013; 2013():254-60. PubMed ID: 24319188 [TBL] [Abstract][Full Text] [Related]
3. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease. Franchini M; Mannucci PM Expert Rev Hematol; 2016 Sep; 9(9):825-30. PubMed ID: 27427955 [TBL] [Abstract][Full Text] [Related]
4. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio. Gadisseur A; Berneman Z; Schroyens W; Michiels JJ Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359 [TBL] [Abstract][Full Text] [Related]
5. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Castaman G; Federici AB; Rodeghiero F; Mannucci PM Haematologica; 2003 Jan; 88(1):94-108. PubMed ID: 12551832 [TBL] [Abstract][Full Text] [Related]
6. Diagnosis and management of von Willebrand disease in Australia. Favaloro EJ; Bonar R; Favaloro J; Koutts J Semin Thromb Hemost; 2011 Jul; 37(5):542-54. PubMed ID: 22102198 [TBL] [Abstract][Full Text] [Related]
7. Epidemiology, diagnosis, and management of von Willebrand disease in India. Ghosh K; Shetty S Semin Thromb Hemost; 2011 Jul; 37(5):595-601. PubMed ID: 22102205 [TBL] [Abstract][Full Text] [Related]
8. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management. Michiels JJ; van Vliet HH Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362 [TBL] [Abstract][Full Text] [Related]
10. Management of inherited von Willebrand disease in 2007. Federici AB; Mannucci PM Ann Med; 2007; 39(5):346-58. PubMed ID: 17701477 [TBL] [Abstract][Full Text] [Related]
11. von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies. James PD; Lillicrap D Am J Hematol; 2012 May; 87 Suppl 1(0 1):S4-11. PubMed ID: 22389132 [TBL] [Abstract][Full Text] [Related]
12. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays? Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279 [TBL] [Abstract][Full Text] [Related]
13. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3. Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574 [TBL] [Abstract][Full Text] [Related]
14. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3. Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493 [TBL] [Abstract][Full Text] [Related]
15. [Diagnosis and management of von Willebrand disease]. Higasa S; Tokugawa T; Sawada A Rinsho Ketsueki; 2018; 59(10):2222-2232. PubMed ID: 30305529 [TBL] [Abstract][Full Text] [Related]
16. Von Willebrand's disease: case report and review of literature. Echahdi H; El Hasbaoui B; El Khorassani M; Agadr A; Khattab M Pan Afr Med J; 2017; 27():147. PubMed ID: 28904675 [TBL] [Abstract][Full Text] [Related]
17. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease. Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936 [TBL] [Abstract][Full Text] [Related]
18. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences. Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467 [TBL] [Abstract][Full Text] [Related]
19. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1. Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358 [TBL] [Abstract][Full Text] [Related]
20. Advances in the diagnosis and management of type 1 von Willebrand disease. Castaman G; Rodeghiero F Expert Rev Hematol; 2011 Feb; 4(1):95-106. PubMed ID: 21322782 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]